Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297733 | 0.81 | HPGD (0.33) | HPGDUSP2LMNAHSD17B10KDM4E | |
| SCHEMBL12775188 | 0.80 | CDK2 (0.37) | HPGDUSP2LMNAHSD17B10KDM4E | |
| SCHEMBL23762179 | 0.80 | HPGD (0.35) | HPGDUSP2LMNAHSD17B10KDM4E | |
| SCHEMBL7019371 | 0.76 | PDPK1 (0.36) | HPGDHSD17B10KDM4EALDH1A1KMT2A | |
| SCHEMBL4525056 | 0.76 | PARP1 (0.33) | HPGDUSP2LMNAHSD17B10KDM4E | |
| Ammonia Solution, Strong SCHEMBL16871771 | 0.75 | PDPK1 (0.35) | HPGDHSD17B10KDM4EALDH1A1PDPK1 | |
| SCHEMBL756217 | 0.74 | KDM4E (0.30) | KDM4E | |
| SCHEMBL1371017 | 0.73 | PDPK1 (0.31) | PDPK1 | |
| SCHEMBL9967827 | 0.73 | FFAR2 (0.33) | HPGDUSP2LMNAHSD17B10KDM4E | |
| SCHEMBL21684954 | 0.73 | CSNK2A1 (0.36) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180002335-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9765019-B2 | Small-molecule-targeted protein degradation | BRANDEIS UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | HPGD 2586/4885USP2 4480/4885LMNA 3431/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | HPGD 2421/4885USP2 2324/4885LMNA 1475/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | HPGD 3567/4885USP2 3041/4885LMNA 954/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | HPGD 3405/4885USP2 2774/4885LMNA 691/4885 |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | HPGD 3556/4885USP2 3541/4885LMNA 3090/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | HPGD 2421/4885USP2 2324/4885LMNA 1475/4885 |
| US-20180002335-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HPGD 2431/4885USP2 1920/4885LMNA 2749/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | HPGD 3405/4885USP2 2774/4885LMNA 691/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HPGD 2431/4885USP2 1920/4885LMNA 2749/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HPGD 2431/4885USP2 1920/4885LMNA 2749/4885 |
| US-20180015093-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HPGD 2431/4885USP2 1920/4885LMNA 2749/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | HPGD 2421/4885USP2 2324/4885LMNA 1475/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | HPGD 2586/4885USP2 4480/4885LMNA 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.